Presentations by Program

Search by Program

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii-calcoaceticusComplex (ABC)

John O'Donnell, ASM Microbe 2019

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

John O'Donnell, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

Sarah McLeod, ASM Microbe 2019

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 b-Lactamase

Adam Shapiro, ASM Microbe 2019

Novel Therapies Targeting Drug-Resistant Gonorrhea

John Mueller, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

Sarah McLeod, ASM Microbe 2019

Scientific Overview of Entasis Pipeline

Ruben Tommasi, ASM Microbe 2019

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

N.J. Onufrak (ICPD), ECCMID 2019

Efficacy of Cefpodoxime proxetil and ETX0282 in a murine UTI model with E. coli and K. pneumoniae

W.J. Weiss (UNTHSC), ECCMID 2019

Discovery of a novel series of Penicillin-Binding Protein 3 inhibitors as monotherapy for Pseudomonas aeruginosa infections: Rational design of biochemical potency and bacterial permeation

Thomas Durand-Reville, ECCMID 2019